![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 32, 24787-24797, August 11, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
,
,
, and

From the
Laboratory of Molecular Oncology, The
Rockefeller University, New York, New York 10021, ¶ Division of
Hematology-Oncology, The New York Presbyterian Hospital-Weill Medical
College of Cornell University, New York, New York 10021, and ** Howard
Hughes Medical Institute, Children's Hospital, Department of
Microbiology and Molecular Genetics, Harvard Medical School,
Boston, Massachusetts 12115
Received for publication, January 27, 2000, and in revised form, May 1, 2000
| |
ABSTRACT |
|---|
|
|
|---|
The Crk family of adaptor proteins
participate in diverse signaling pathways that regulate growth
factor-induced proliferation, anchorage-dependent DNA
synthesis, and cytoskeletal reorganization, important for cell adhesion
and motility. Using kidney epithelial 293T cells for transient
co-transfection studies and the nerve growth factor (NGF)-responsive
PC12 cell line as a model system for neuronal morphogenesis, we
demonstrate that the non-receptor tyrosine kinase c-Abl is an
intermediary for NGF-inducible c-Crk II phosphorylation on the negative
regulatory Tyr222. Transient expression of a c-Crk II
Tyr222 point mutant (c-Crk Y222F) in 293T cells induces
hyperphosphorylation of paxillin on Tyr31 and enhances
complex formation between c-Crk Y222F and paxillin as well as c-Crk
Y222F and c-Abl, suggesting that c-Crk II Tyr222
phosphorylation induces both the dissociation of the Crk SH2 domain
from paxillin and the Crk SH3 domain from c-Abl. Interestingly, examination of the early kinetics of NGF stimulation in PC12 cells showed that c-Crk II Tyr222 phosphorylation preceded
paxillin Tyr31 phosphorylation, followed by a transient
initial dissociation of the c-Crk II paxillin complex. PC12 cells
overexpressing c-Crk Y222F manifested a defect in cellular adhesion and
neuritogenesis that led to detachment of cells from the extracellular
matrix, thus demonstrating the biological significance of c-Crk II
tyrosine phosphorylation in NGF-dependent morphogenesis.
Whereas previous studies have shown that Crk SH2 binding to paxillin is
critical for cell adhesion and migration, our data show that the
phosphorylation cycle of c-Crk II determines its dynamic interaction
with paxillin, thereby regulating turnover of multiprotein complexes, a
critical aspect of cytoskeletal plasticity and actin dynamics.
The Crk adaptor proteins, first described as the product of an
avian oncogene, v-crk, contain Src homology 2 (SH2)1 and SH3 domains that
serve as binding sites for a diverse set of signaling proteins (1-3).
A number of studies with v-Crk have established a paradigm in which SH2
and SH3 domain-coupled signals positively regulate growth factor-
(4-6) as well as integrindependent pathways (7, 8). Recent
studies have also linked the cellular homologs of v-Crk, namely c-Crk
I, c-Crk II, and CrkL (9, 10), with cellular proteins that induce Rac
GDP-GTP exchange activity (11, 12), cytoskeletal reorganization (13),
cellular migration (14), and anchorage-dependent cell
growth (15). Although c-Crk and v-Crk may have some overlapping
functions due to their SH2 and N-terminal SH3 domains, both c-Crk II
and CrkL contain an additional SH3 domain in the C terminus (10, 16) as
well as a conserved tyrosine (c-Crk II Tyr221 and CrkL
Tyr207 in the human isoforms; c-Crk II Tyr222
in the avian isoform) that can be phosphorylated by the non-receptor tyrosine kinase c-Abl (17, 18). Moreover, c-Crk Tyr222 is
flanked by an AQPS motif in the linker region, which when phosphorylated, conforms to a consensus Crk SH2 binding site and has
been hypothesized to negatively regulate c-Crk function(s) by forming
an intramolecular bridge (19). Although these studies suggest a model
of c-Crk regulation that is analogus to that of Src family tyrosine
kinases upon phosphorylation by C-terminal Src kinase (CSK) (20), the
underlying mechanism by which phosphorylated Tyr222
modulates c-Crk II biological functions is not well understood.
Following their activation by binding to extracellular matrix
molecules, integrins couple with intracellular tyrosine kinases such as
FAK, Pyk2, Src, and c-Abl, leading to the formation of complex
signaling networks involving kinases, their substrates, and adaptor
proteins (21-25). Two of the major tyrosine-phosphorylated proteins
that orchestrate the assembly of focal adhesions are paxillin and
p130cas (26, 27). Although unrelated structurally, both genes
encode multidomain proteins that can associate with and become
phosphorylated by various nonreceptor tyrosine kinases (FAK, Src, CSK,
and c-Abl for paxillin and FAK and Src family members for
p130cas) (25, 28). Furthermore, after tyrosine phosphorylation,
both paxillin and p130cas present multiple docking sites for
the Crk SH2 domain (29-31), thereby recruiting additional signaling
proteins to focal adhesions via the Crk N-terminal SH3 domain (3).
Accordingly, the binding of DOCK180 to p130cas·Crk complex
has been implicated in altering cell morphology via the activation of
Rac1 (32), and mutations in either the Crk SH2 domain or the
Crk-binding sites of p130cas have been shown to impair cell
migration in carcinoma cells (14). Recently, it has also been shown
that phosphorylation of Tyr31 and Tyr118 on
paxillin regulates cell migration through an association of Crk in
NBT-II cells (33), suggesting that Crk binding to paxillin and
p130cas may have redundant functions.
Although integrin-mediated tyrosine phosphorylation of paxillin and
p130cas has been best characterized, various growth factors
including insulin, epidermal growth factor, and platelet-derived growth factor also induce rapid changes in cell shape that correlate with
tyrosine phosphorylation of paxillin and p130cas (34-36).
Although these results clearly support a model of cross-talk between
receptor tyrosine kinases and molecules residing in focal adhesions, it
remains unclear whether Crk proteins might be signaling intermediates
that orchestrate these interactions. Using the PC12 cells as a model
system of nerve growth factor (NGF)-induced neuronal morphogenesis
(37), we and others have previously shown that NGF induces rapid actin
reorganization and membrane ruffling that accompany alterations in cell
shape (38), with concomitant tyrosine phosphorylation of c-Crk II and
paxillin (4, 39). In the present study, we describe a novel pathway in
which activation of the NGF receptor Trk A leads to c-Abl-mediated
phosphorylation of c-Crk II at Tyr222, which catalyzes the
dissociation of the Crk SH2 domain from paxillin and the dissociation
of the Crk SH3 domain from c-Abl. The significance of this mechanism is
highlighted by the findings that a c-Crk II Tyr222 mutant
(c-Crk Y222F), while causing constitutive complex formation between
c-Crk and paxillin as well as c-Crk and c-Abl, impairs NGF-dependent cellular spreading and neurite outgrowth.
Thus, although previous studies have indicated that Crk binding to
paxillin and p130cas is critical for cell adhesion and
motility, we propose that the dynamic nature of substratum adhesion and
detachment, a critical aspect of NGF-induced morphogenesis, is
determined in part by the phosphorylation/dephosphorylation cycle of
c-Crk II on Tyr222.
Cells and Tissue Culture--
Fibroblasts immortalized from Abl
( Antibodies--
Anti-peptide polyclonal antibodies that
recognize Tyr222-phosphorylated c-Crk II (pCrk) were
provided by Michiyuki Matsuda (National Institute of Infectious
Diseases, Tokyo, Japan) (40), and monoclonal anti-Src antibodies were
from Joan Brugge (Harvard Medical School). Anti-TrkA polyclonal
antibodies were generated as described previously (41). Commerically
available antisera were purchased from the indicated sources:
anti-phosphotyrosine (Tyr(P)) antibodies PY20 (Transduction
Laboratories), 4G10 (Upstate Biotechnology, Inc.), and PY-99 (Santa
Cruz Biotechnology); anti-FLAG monoclonal M2 (Eastman Kodak Co.);
anti-c-Abl monoclonal 8E9 (Pharmingen) and anti-c-Abl monoclonal Ab-3
(Calbiochem); anti-paxillin monoclonal (Zymed Laboratories
Inc. or Transduction Laboratories); anti-FAK, anti-c-Crk II, and
anti-p130cas (all from Santa Cruz Biotechnology).
Plasmid Constructions and DNA Transfection--
The c-crk
II, c-abl, and trkA plasmids and respective
mutants have been previously described. Briefly, avian c-crk
II and c-crk Y222F were subcloned into the pEBG vector,
driven by the human elongation factor 1-
To generate clonal PC12 cell lines stably overexpressing Crk protein,
cells were transfected with 18 µg of pEBG-c-Crk II or pEBG-c-Crk
Y222F plasmid DNA and 2 µg of pMEXneo using the
LipofectAMINETM reagent (Life Technologies, Inc.), and cell lines were
expanded as described previously (4). We found that a high level of
c-Crk II or c-Crk Y222F expression was unstable in PC12 cells over
multiple passage.2 Therefore,
cell lines were routinely monitored for consistent levels of of c-Crk
II or c-Crk Y222F expression, and when necessary, aliquots of early
passaged lines were re-established from liquid nitrogen stocks. For
transient transfections, subconfluent cultures of 293T cells were
transfected for 4 h in serum-free Opti-MEM with plasmid DNAs using
the LipofectAMINE reagent (Life Technologies, Inc.), and cells were
lysed 48 h after transfection. Where applicable, 293T cells were
stimulated with 100 ng/ml NGF (Collaborative Biomedical Sciences) in
serum-free DMEM before lysis.
Generation of and Infections with Recombinant c-Crk-containing
Retroviruses--
A cDNA encoding full-length c-Crk II or c-Crk
Y222F was subcloned into a bicistronic pCX-bsr retroviral vector in
which c-Crk II and green fluorescent protein (GFP) are expressed from
the same transcript via an internal ribosome entry site.
c-Crk-expressing virus was produced by LipofectAMINE-mediated
transfection of 1.0 µg of pCX-crk DNA together with 1.0 µg of
pC-Eco retroviral DNA into the Bosc23 replication incompetent
ecotropic packaging line (RetromaxTM, Imgen) according to the
manufacturer's protocols. Transfection media was replaced with 10 ml
of DMEM containing 10% fetal calf serum for 24 h and then
collected and frozen at Flow Cytometry and Fluorescence-activated Cell Sorter (FACS)
Sorting--
PC12 cells were incubated with
phosphatidylethanolamine-conjugated anti-Annexin V (Chemicon) in
the binding buffer (5 mM CaCl2, 140 mM NaCl, 10 mM Hepes, pH 7.4) for 30 min at
4 °C, and stained cells were analyzed using FACScan. For sorting,
PC12 cells infected with each GFP expression vector were sorted by
green fluorescence using FACStarPlus (Becton Dickinson Inc, San Jose,
CA). For analysis of adherent and non-adherent pools, PC12 cells were
infected with pCX virus, and 3 days after infection, poorly adherent
cells were collected by gentle trituration and pooling the media after
washing in PBS. The adherent cells were harvested mechanically in PBS containing 10 mM EDTA. The ratio of total GFP-positive
cells in each population was quantified by flow cytometry.
Immunoprecipitation and Western Blotting--
293T cells were
lysed in ice-cold HNTG buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, and 1% Triton X-100) containing 0.1 mM sodium molybdate, 1 mM sodium vanadate,
1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml
aprotinin. PC12 cells were lysed in TLB buffer (1% Nonidet P-40, 20 mM Tris, pH 7.5, 137 mM NaCl, 2 mM EDTA, 20 mM Protein Kinase Assays--
Immune complex kinase assays for
c-Abl were performed using [ Immunofluorescence and Confocal Microscopy--
Wild-type PC12
and c-Crk II- or c-Crk Y222F-expressing PC12 cells were plated on glass
coverslips coated with collagen type IV and cultured in the presence of
NGF for the indicated times (5). After rinsing with PBS, cells were
fixed at room temperature for 30 min in 3% paraformaldehyde,
permeabilized with 0.2% Triton X-100 for 5 min, and incubated with
anti-paxillin monoclonal antibody (Zymed Laboratories
Inc., diluted 1:200 in PBS containing 0.2% gelatin). After
washing, cells were incubated with fluorescein-conjugated goat
anti-mouse IgG (1:200 dilution). To detect F-actin, cells were
incubated with rhodamine-conjugated phalloidin (Molecular Probes;1:200
dilution) for 30 min, washed in PBS, and mounted in Vectashield (Vector
Labs). To assess the extent of plasma membrane flattening, cells were
labeled with BSA-conjugated DiI (kindly provided by Sushmita
Mukherjee, Weill Medical College of Cornell University) for 1 min,
washed in PBS, and immediately fixed in 3% paraformaldehyde. Cells
were examined with an epifluorescence microscope at 100× (Nikon) or
with a confocal laser-scanning microscope (Bio-Rad) using 60×
objective, generating 0.54-µm sections. Serial X-Y sections obtained
from the confocal microscope were reanalyzed in the x-z
plane using NIH Image software to make height and area measurements.
Height measurements were made by averaging the height of three
z-sections per cell. Area measurements were calculated by
tracing the outline of a representative slice.
Cell Adhesion Assays--
Cell attachment was assessed according
to the methods of Tomaselli (45). Briefly, PC12 cells were plated in
96-well flat-bottomed plates coated with BSA (1 mg/ml),
poly-D-lysine (1 mg/ml), or collagen IV (2 mg/ml). Cells
were incubated in media containing 3% serum and 100 ng/ml NGF for
6 h at 37 °C. Unattached cells were dislodged from the bottom
of the well by three washes in PBS. Attached cells were fixed in
glutaraldehyde and stained with 0.5% trypan blue. Quantitation of
attached cells was performed by measuring absorbance at 590 nm of
individual wells using a microtiter plate reader. Each value represents
the mean and S.D. of determinations made on triplicate cultures
performed in parallel and is expressed as a percentage of cell
attachment on the indicated substrate relative to the cell attachment
to poly-D-lysine.
Stimulation of Cells with NGF Induces Phosphorylation of Paxillin
on Tyr31 and c-Crk II on Tyr222--
When PC12
cells are stimulated to differentiate with NGF, multiple proteins,
including c-Crk II and paxillin, become tyrosine-phosphorylated within
minutes after growth factor stimulation (4, 39, 46). To identify the
residues on paxillin and c-Crk II that are tyrosine-phosphorylated following NGF stimulation, Tyr to Phe point mutants of paxillin or
c-Crk II were co-expressed with the NGF receptor TrkA in human epithelial kidney (HEK) 293T cells (Fig.
1). Mutagenesis of the three putative
high affinity Crk SH2 binding motifs in the N-terminal region of
paxillin (Tyr31-Ser-Tyr-Pro,
Tyr118-Ser-Phe-Pro, and Tyr182-Val-Ile-Pro
(26)) virtually abrogated NGF-inducible paxillin phosphorylation (Fig.
1A, lanes 2 versus 3). To map the sites of
NGF-inducible paxillin phosphorylation in more detail,
Tyr31, Tyr118, and Tyr182 residues
were mutated singly or in combination and co-expressed with TrkA in
293T cells (Fig. 1B). Paxillin mutants containing a Y31F
substitution exhibited the most significant reduction (>70%) in Trk
A-dependent phosphorylation after NGF treatment (Fig.
1B), whereas a Y113F,Y182F paxillin double mutant with an
intact Tyr31 was less affected. To demonstrate that
Tyr31 represents the major NGF-inducible Crk binding motif
in paxillin, 293T cells co-expressing TrkA and c-Crk II with
either FLAG-tagged paxillin, FLAG-tagged Y31F paxillin, or FLAG-tagged
paxillin Y31F,Y118F,Y182F paxillin, were immunoprecipitated with
anti-Crk antibodies (Fig. 1C). As indicated, mutation
of Tyr31 in paxillin significantly disrupted binding to
c-Crk II, which was not further abrogated upon co-expression of
Y31F,Y118F,Y182F paxillin with TrkA and c-Crk II (Fig. 1C,
inset). These results indicate that paxillin
Tyr31 is the major site mediating c-Crk II interaction
following NGF stimulation in vivo.
Although Tyr222 is a major site for c-Crk II
phosphorylation in vitro (17), we sought to verify that the
same tyrosine residue becomes tyrosine phosphorylated in
vivo following TrkA activation. Toward this goal, wild-type c-Crk
II or the point mutant of c-Crk II at Tyr222 (c-Crk Y222F) were
coexpressed with TrkA in 293T cells. Using either an
anti-phosphotyrosine (Tyr(P)) antisera or phospho-c-Crk-specific
Tyr222 (pCrk) antisera, we found that wild-type c-Crk II,
but not c-Crk Y222F, was phosphorylated upon NGF treatment (Fig.
1D, compare lanes 2 and 3 in
respective panels). Together, these observations suggest that c-Crk II
is phosphorylated exclusively on Tyr222 upon NGF
stimulation in vivo.
NGF-inducible Tyrosine Phosphorylation of c-Crk II and of Paxillin
Requires c-Abl--
A recent study by Yano et al. (47)
reports an interaction between c-Abl and TrkA in both PC12 cells and
after cotransfection into 293T cells. Since c-Abl is known to interact
with c-Crk II (17) and with paxillin (23), it may be a likely candidate to mediate the NGF-induced tyrosine phosphorylation of these proteins. To assess the role of c-Abl in NGF-induced c-Crk II phosphorylation, c-Crk II and TrkA were coexpressed in fibroblasts derived form Abl
(
To determine whether NGF-inducible paxillin tyrosine phosphorylation is
also dependent on c-Abl, FLAG-tagged paxillin and TrkA were transiently
co-expressed with either wild-type c-Abl or the kinase-deficient mutant
K290M c-Abl (Fig. 2B). Overexpression of wild-type c-Abl
results in high levels of tyrosine phosphorylation of paxillin, which
was not significantly augmented by TrkA expression (Fig. 2B,
lanes 2 versus 3, Tyr(P) (anti-pTyr) blot).
However, expression of K290M c-Abl abolished the phosphorylation of
paxillin following Trk A activation (lane 4). Indeed, both
wild-type and K290M c-Abl formed stable complexes with paxillin in
co-precipitation analysis (Fig. 2B, anti-Abl
blot; lanes 2-4), although as expected, no
paxillin-associated kinase activity was detected when K290M c-Abl was
expressed (Fig. 2B, Abl kinase assay; lane
4).
Other nonreceptor tyrosine kinases such as FAK and Src have been
implicated in the integrin-dependent tyrosine
phosphorylation of paxillin on Tyr31 and Tyr118
(30, 48), which in turn create Crk SH2 binding sites (29, 30). While
the results in Fig. 2B demonstrate that c-Abl can also
phosphorylate paxillin, it is not clear whether c-Abl also requires FAK
or Src following TrkA activation. To address this, mouse embryo
fibroblasts (MEF) derived from wild-type or FAK ( Complex Formation between c-Crk II and Paxillin and c-Crk II and
Abl Is Regulated by c-Crk II Tyr222
Phosphorylation--
Whereas the phosphorylation of Tyr31
in paxillin induces an association between Crk and paxillin (Fig.
1C), Tyr222 phosphorylation in c-Crk II induces
an intramolecular association of the Crk SH2 domain and is expected to
lead to a dissociation of Crk from paxillin (17). To examine the effect
of c-Crk Tyr222 phosphorylation on the cellular turnover of
Crk/paxillin complexes, 293T cells co-expressing TrkA, FLAG-tagged
paxillin, and wild-type c-Crk II or Y222F c-Crk were analyzed (Fig.
3). Expression of c-Crk Y222F resulted in
an increased level of cellular paxillin tyrosine phosphorylation (Fig.
3A, lanes 2 and 3 in anti-Tyr(P) (anti-pTyr) blot), and a much greater proportion of the
total pool of c-Crk Y222F existed as a complex with paxillin compared with the wild-type c-Crk II, as evident from co-immunoprecipitation analysis (Fig. 3B). Interestingly, only the unphosphorylated
pool of c-Crk II interacted with paxillin, and the
Tyr222-phosphorylated pool of c-Crk II was found
exclusively in the supernatant. These results suggest that at steady
state, there is an equilibrium between two separate pools of c-Crk II:
(i) unphosphorylated c-Crk II, which complexes with
tyrosine-phosphorylated paxillin, and (ii) tyrosine-phosphorylated
c-Crk II, which is monomeric.
Given the hyperphosphorylation of paxillin in cells expressing Y222F
c-Crk II and the fact that paxillin can serve as a substrate for Abl
following NGF stimulation, we investigated the effect of Y222F c-Crk II
on the cellular interaction between c-Abl and the SH3 domain of Crk
(Fig. 4A). When 293T cells
expressing wild-type c-Abl and c-Crk Y222F were immunoprecipitated with
anti-Crk antibodies, the activity of c-Abl associated with c-Crk Y222F
was more than 4-fold greater than that associated with equivalent
amounts of wild-type c-Crk II (Fig. 4A and
inset), and importantly, there was much more Abl
co-precipitating with c-Crk Y222F under these conditions (Fig.
4A, top panel). No Abl activity associated with the c-Crk W170K SH3 domain mutant (not shown), confirming previous studies that the interaction between Abl and Crk is dependent on the
Crk SH3 domain (17). Interestingly, when replicate lysates to those
used in Fig. 4A were immunoprecipitated with anti-FLAG antibodies (to precipitate paxillin), there was also a much greater pool of Abl co-precipitating with paxillin in c-Crk II Y222F-expressing 293T cells, as well as a greater pool of Crk in these complexes (Fig.
4B). Collectively, the results in Figs. 3 and 4 indicate that Crk Tyr222 phosphorylation actively induces both the
dissociation of the Crk SH2 domain from paxillin and the Crk SH3 domain
from Abl and that mutagenesis of the Tyr222 in c-Crk
potentiates Abl-dependent paxillin tyrosine phosphorylation by inducing a persistent Crk/paxillin/Abl protein complex in cells.
NGF-induced Dissociation of c-Crk II-Paxillin Complex in PC12 Cells
Is Also Inhibited by c-Crk Y222F--
The transient transfection
experiments in 293T cell system suggests a model in which c-Crk II
Tyr222 phosphorylation is required for the regulated
turnover of Crk-paxillin-Abl protein complexes. To test the biological
importance of this model during neuronal differentiation, we first
investigated the kinetics of c-Crk II and paxillin tyrosine
phosphorylation in the NGF-treated PC12-615 cell line (41) (Fig.
5A). An early time course
analysis revealed that whereas TrkA activation was detectable 1 min
after NGF stimulation, tyrosine phosphorylation of c-Crk II was
apparent by 2 min and persisted for at least 1 h, with an upward
electromobility shift of c-Crk II (Fig. 5B). Although basal
tyrosine phosphorylation of paxillin was observed in unstimulated cells
(Fig. 5C, lane 1), NGF-augmented paxillin
phosphorylation was detectable 5 min after NGF stimulation and
maintained for up to 3 h after NGF treatment (Fig. 5C
and data not shown).
The fact that NGF-induced c-Crk II Tyr222 phosphorylation
precedes paxillin phosphorylation predicts that c-Crk II may initially dissociate from an existing pool of tyrosine-phosphorylated paxillin. To test this hypothesis, wild-type c-Crk II or c-Crk Y222F were transiently expressed in PC12-615 cells using recombinant
Crk-expressing retrovirus (Fig. 5D). In the cells
overexpressing wild-type c-Crk II, a complex of c-Crk II and paxillin
was detectable in unstimulated cells, and this complex dissociated
within 2 min of NGF addition (Fig. 5D, lanes 2 and 3). In contrast, expression of c-Crk Y222F promoted
Crk/paxillin association in the basal state and resulted in
hyperphosphorylation of paxillin. In agreement with the results in 293T
cells, NGF stimulation of these cells failed to induce the dissociation
of paxillin from the anti-Crk immunocomplex (Fig. 5D,
lanes 4 and 5).
Mutation of c-Crk II Tyr222 Impairs Cellular Adhesion
and NGF-induced Neuritogenesis--
The enhanced interaction of
hyperphosphorylated paxillin with c-Crk Y222F could either positively
or negatively modulate the cytoskeletal dynamics that are critical for
NGF-induced neuritogenesis. To examine the effects of c-Crk Y222F
overexpression during NGF-inducible neuritogenesis, wild-type c-Crk II
and c-Crk Y222F were expressed in PC12 cells by stable gene transfer.
Independent PC12 cell lines overexpressing c-Crk II or c-Crk Y222F at
2-3 times the endogenous c-Crk II levels were clonally expanded (Fig.
6A). Whereas parental PC12
cells or c-Crk II-overexpressing PC12 cells demonstrated rapid c-Crk II
tyrosine phosphorylation following NGF stimulation, no endogenous c-Crk
II tyrosine phosphorylation was observed in NGF-treated c-Crk
Y222F-expressing cells (Fig. 6A), a result confirmed in
several independent clones. When NGF-stimulated neurite outgrowth was
compared between the three cell types, we found that the c-Crk Y222F-expressing PC12 cells tended to form aggregates with short or no
visible neuritic processes, even after 72 h of NGF treatment (Fig.
6B, panel vii). To determine if paxillin
localization was perturbed upon c-Crk Y222F expression,
immunolocalization of paxillin was performed. As shown in Fig.
6B, punctate F-actin and paxillin staining were localized to
the leading edges of the growth cones in cells expressing wild-type
c-Crk II (panels ii and v for native PC12
cells and panels iii and vi for c-Crk
II-expressing PC12 cells), consistent with the formation of normal
focal contacts. With Y222F c-Crk-expression, paxillin localized
diffusely in the cytoplasm, particularly in the perinuclear region, but
lacked discernable localization in the short processes (Fig.
6B, panels viii and ix).
The possible mislocalization of paxillin in c-Crk Y222F-expressing PC12
cells together with the established role of paxillin and c-Crk II in
focal adhesion assembly and in integrin-mediated cellular adhesion
prompted us to evaluate the effects of Y222F c-Crk on cell attachment
and adherence to extracellular matrix (Fig.
7). Previous studies have documented that
PC12 cells readily attach to poly-D-lysine and collagen IV
(45). Although attachment to collagen IV requires integrin activation,
cells attach to poly-D-lysine in an integrin-independent
manner (50). In a quantitative cell attachment assay, PC12 cells were
plated on either BSA, poly-D-lysine, or collagen IV in the
presence of 50 ng/ml NGF for 6 h. (Fig. 7A). Native PC12 cells adhered
to collagen IV and exhibited 85% attachment when normalized to
adherence on poly-D-lysine (Fig. 7A). In
contrast, c-Crk Y222F-expressing PC12 cells were significantly impaired
in their ability to attach to collagen IV (approximately 25%) yet
maintained ability to adhere to poly-D-lysine.
Interestingly, PC12 cells overexpressing wild-type c-Crk II also
exhibited a modest decrease in adhesion on collagen IV, despite
apparently normal neuritogenesis. Since a decrease in substrate
adhesion might have a direct effect on cellular flattening, an
area/height ratio analysis was carried out as an independent criterion
for assessing the effect of c-Crk Y222F on PC12 cytoskeleton (Fig. 7B). Using BSA-DiI (which stains plasma membranes)
followed by optical sectioning with confocal microscopy, we found that
both native and c-Crk II-expressing PC12 cells exhibit similar
area/height ratios, whereas c-Crk Y222F expression changes the cell
shape from flat and polygonal to round, as revealed by the decrease (>50%) in area/height ratios.
Because stable cell lines exhibiting defects in cellular adhesion may
result in instability of c-Crk expression with passaging, transient
overexpression of c-Crk II or c-Crk Y222F in the PC12-615 cells with
the marker gene GFP was utilized for further analysis (Fig.
7C). Consistent with the results using stable PC12
transfectants, GFP-positive cells overexpressing c-Crk Y222F exhibited
a round morphology compared with those expressing GFP alone (not
shown). Similarly, in a quantitative cell attachment assay, the ratio of poorly adherent/attached GFP-positive cells was approximately 3-fold
higher in the Crk Y222F-expressing cells compared with the vector
alone-infected cells, whereas cells overexpressing wild-type c-Crk II
exhibited a modest increase in detachment (a 1.6-fold increase). When
GFP-positive gated cells were counter-stained with
phosphatidylethanolamine-conjugated annexin V, there was no
difference in staining in the GFP-positive and -negative cells, indicating that the loss in cellular adhesion does not result from
apoptosis (data not shown).
In the present study, we have investigated the role of
Tyr222 phosphorylation in the c-Crk II adaptor protein and
found that c-Crk II phosphorylation is critical for normal cytoskeletal
signaling and cellular adhesion. Overexpression of c-Crk Y222F in cells stabilized an association between c-Crk II and paxillin and c-Abl, resulting in persistent complex formation of these proteins and hyperphosphorylation of paxillin and led to a defect in cell adhesion and neuritogenesis in PC12 cells. We propose that sequential tyrosine phosphorylation of c-Crk II on Tyr222 and paxillin on
Tyr31, induced following NGF stimulation, permits rapid
turnover of multiprotein complexes that regulate cytoskeletal
plasticity and actin reorganization, a strategy that may also be
adopted for other cell type-specific morphogenic events.
The mechanism by which c-Crk II promotes cell adhesion and migration
has been mainly explored in fibroblasts and epithelial cells during
adhesion and cell migration along the extracellular matrix (7, 12, 14,
33, 51). In such cells, integrin receptor activation results in
tyrosine phosphorylation of p130cas and paxillin, thereby
recruiting c-Crk II via its SH2 domain (25). c-Crk II in turn can
interact with downstream effectors such as the guanine nucleotide
exchange proteins C3G and DOCK180 (11, 52). When coupled, the regulated
binding of c-Crk II to p130cas may serve as a regulator of
stress fiber formation (13) and cell migration (12, 14), leading to the
activation of both JNK- and Rac1-dependent signaling
pathways (15, 32, 53, 54). The present findings that c-Crk Y222F
overexpression manifests an apparent defect in cytoskeletal
organization, despite leading to persistent complex formation between
Crk, paxillin, and c-Abl implies that purely inductive signaling is
insufficient for the effects of Crk on cellular adhesion and migration.
We posit that the effects of c-Crk II on cellular adhesion are
determined by a balance of positively and negatively acting signals
transmitted through the differential phosphorylation of c-Crk II on
Tyr222.
Following stimulation of cells with NGF, we have shown here that the
non-receptor tyrosine kinase c-Abl is an intermediary for
TrkA-inducible phosphorylation of c-Crk II on Tyr222 and
paxillin on Tyr31. Although FAK is clearly implicated in
paxillin phosphorylation and in integrin-mediated focal adhesions and
cell spreading (30, 51), there is also precedent for FAK-independent
pathways in such processes (55). For example, in CML cells or myeloid
cells expressing BCR-Abl, CrkL has been shown to link BCR-Abl with
paxillin, leading to paxillin phosphorylation on Tyr31 and
Tyr118 (56). Moreover, studies in fibroblasts have shown
that a pool of cytoplasmic c-Abl associates with and tyrosine
phosphorylates paxillin after integrin-dependent adhesion
(23). Recent results by Yano et al. shows that c-Abl can
form a physical complex with Trk A (47) that may in part explain
previous studies showing an association between TrkA and c-Crk II in
co-immunoprecipitation studies (57, 58). Interestingly, mapping studies
between TrkA and c-Abl indicated that c-Abl interacts with TrkA through
the juxtamembrane region of TrkA, a region also known to be required for TrkA-mediated neurite outgrowth (59). In future studies it should
be important to examine whether juxtamembrane mutants of TrkA fail to
induce c-Crk II and paxillin phosphorylation following NGF stimulation.
The findings that NGF simultaneously induces Tyr222
phosphorylation in c-Crk II and Tyr31 phosphorylation in
paxillin suggests that a cyclical model for Crk and paxillin
association has important implications in vivo. Early
changes in the association of paxillin and c-Crk II and CrkL have also
been observed following stimulation of cells with insulin-like growth
factor and epidermal growth factor (60, 61). Hence, we propose that the
breakdown of focal contacts may occur initially (within 5 min of NGF
treatment) and is followed by cyclical turnover of c-Crk II/paxillin
complexes (after 5 min of NGF treatment). Even though c-Crk II and
paxillin tyrosine phosphorylation appears unchanged at steady state,
our model predicts the presence of (i) phosphorylated c-Crk II, which
is monomeric, and (ii) dephosphorylated c-Crk II, which complexes with
c-Abl and with tyrosine-phosphorylated paxillin (Fig. 8). Thus, in a dynamic equilibrium, c-Abl "regenerates" monomeric c-Crk II via Tyr222 phosphorylation, which results in the dissociation
of phospho-c-Crk II from tyrosine-phosphorylated paxillin
(SH2-dependent) and from c-Abl (SH3-dependent).
Although a definitive proof of this hypothesis may require "real
time" analysis, the enhanced association of hyperphosphorylated
paxillin and c-Abl with the c-Crk Y222F mutant (this study) is
consistent with the dynamic molecular interactions, as suggested by
this model. Accordingly, when the pathway required for turnover is
impaired upon introduction of the Y222F mutation, c-Abl-mediated
phosphorylation of paxillin is not counterbalanced by the formation of
phospho-c-Crk II monomer. As a result, phosphorylated paxillin remains
associated with c-Crk (Y222F) and, presumably, further phosphorylated
by c-Abl within the complex (Fig. 8). Such constitutive tethering of
protein complex might also lead to the inability of paxillin to reach a
cellular destination, such as focal adhesions, and hence, lead to
defects in cellular adhesion and impaired neuritogenesis. Interesting,
in a recent study with CrkL, Y207F CrkL, which corresponds to Y222F in
c-Crk II, increases the level of paxillin tyrosine phosphorylation
compared with native CrkL (18), suggesting there may be functional
redundancy of Crk proteins regulating cell adhesion.
The fact that c-Crk Tyr222 phosphorylation disrupts the
binding of Crk to both paxillin and c-Abl suggests that such
phosphorylation functions to sequester the binding surfaces of both
domains in the native structure. Although NMR spectroscopy analysis on
c-Crk II indicates the SH2 domain of Crk binds phosphorylated
Tyr222 (19) and suggests a conformation change in the Crk
SH3 domain, these studies did not address whether the binding affinity
of the Crk SH3 domain was changed. The crystal structures of the Src
and Hck kinases (62, 63) may also provide insight into how
Tyr222 phosphorylation in Crk may function. Indeed, it has
long been realized that Src kinases are inhibited by tyrosine
phosphorylation in the C-terminal Tyr527 residue
(64-66). However, it has been recently shown that intramolecular binding of phosphorylated Tyr527 tail to the SH2 domain
indirectly inhibits Src enzymatic activity by facilitating a second
intramolecular interaction between the SH3 domain and the Src catalytic
domain (SH1) (62). Given the importance of Tyr222
phosphorylation in regulating c-Crk binding affinities, detailed structural studies are warranted to ascertain how phosphorylation of
Tyr222 affects the interdomain structures of the SH2 and
SH3 domains.
Given the cyclical nature of c-Crk II/paxillin binding and turnover, an
equally important issue pertains to the dephosphorylation of c-Crk II
Tyr222 and of paxillin. Currently, however, there is no
known Crk-specific phosphatase, despite the finding that treatment of
cells with the tyrosyl phosphatase inhibitor sodium vanadate
phosphatase increases c-Crk II tyrosine phosphorylation in
vivo.2 In contrast, numerous phosphatases,
including Shp2, PTP-PEST, PTP- In summary, we propose a model based on the differential tyrosine
phosphorylation of c-Crk II to account in part for rapid and dynamic
cytoskeletal reorganization following growth factor stimulation. Our
data are consistent with the emerging evidence that c-Crk II- and
Crk-associated proteins may exert specialized functions in the
generation, dissipation, and regeneration of mechanochemical force
required for cell shape changes. Future research will focus on
mutations that disrupt the Crk/paxillin/Abl circuit to specifically
address the complexity of molecular cross-talk underscored by the
present study.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
) or FAK (
/
) homozygous mice were generous gifts of David
Baltimore (California Institute of Technology) and Tadashi Yamamoto
(Tokyo University), respectively, and were maintained in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% calf serum. Abl
(
/
) fibroblasts engineered to stably re-express wild-type c-Abl
after DNA transfection with pBabe-c-Abl were a gift from Tohru Ouchi
(Mount Sinai School of Medicine). Wild-type PC12 cells were maintained
in DMEM supplemented with 10% calf serum and 5% horse serum.
TrkA-overexpressing PC12-615 cells, c-Crk II overexpressing PC12 cells,
and c-Crk Y222F-expressing PC12 cells were maintained in DMEM
containing 10% calf serum and 5% horse serum with 200 µg/ml G418.
293T cells and Bosc23 ecotropic virus-packaging cell lines were
grown in DMEM supplemented with 10% fetal calf serum.
promotor (42). Wild-type
and kinase-deficient (K290M) murine type IV c-abl (43) were
provided by David Baltimore as described previously (44) and were
subcloned into pcDNA3 (Invitrogen). Expression plasmids for TrkA
(pcDNA3-trkA), kinase-dead c-Src (pBabe K295M src), or kinase-dead
FAK (pCR K454M FAK) were provided by David Kaplan (McGill University),
Hisataka Sabe (Osaka Bioscience institute), and Steven Hanks
(University of Virginia), respectively. To construct a FLAG
epitope-tagged paxillin expression vector, a full-length chicken
paxillin cDNA in pGEX (26) was digested with BamHI and
then subcloned into pFLAG-CMV2 (Eastman Kodak) using
BamHI-EcoRI linkers. Site-directed mutagenesis
was performed using the QuikChange site-directed mutagenesis kit
(Stratagene). The following sequences (5'-3') of the sense mutagenic
oligonucleotides were used, with mismatches indicated in uppercase: for
the Y31F mutation, gag gaa acg cct tTc tcc tac cca act g; for Y118F,
gag gaa cac gtg tTc agc ttc cca aac; and for Y182F, g acc gga cct cac
tT t gtc atc cca gag. All point mutations were confirmed by DNA sequencing.
70 °C. The cells were re-fed with fresh
DMEM (10 ml) and maintained for an additional 16 h. A total of 20 ml of virus-containing tissue culture media were pooled, centrifuged at
15,000 × g for 3 h, and resuspended into 2.0 ml
of PC12 cell medium containing 7 µg/ml Polybrene. PC12 cells, seeded
at 50% confluency, were infected with the concentrated stock for
48 h, and medium was changed and incubated for an additional
48 h. Between 20 and 30% PC12 cells were GFP-positive, and high
levels of ectopic protein expression was detectable for up to 1 week.
-glycerophosphate, 2 mM sodium
pyrophosphate, and 10 mM NaF) containing phosphate and
protease inhibitors. Cleared lysates were incubated with specific
antibodies (typically 1-2 µg) for 3 h at 4 °C followed by
incubation with protein A-Sepharose beads (Amersham Pharmacia Biotech)
or protein G plus-Sepharose (Santa Cruz Biotechnology). After washing
with lysis buffer, immune complexes were subjected to SDS-PAGE and
Western blot analysis using standard protocols. Blots were incubated
with the indicated primary antibodies and the appropriate horseradish
peroxide-conjugated secondary antibodies, followed by detection using
enhanced chemiluminescence (ECL) reagent (Renaissance, NEN Life
Science Products).
-32P]ATP and GST-Crk
120-225 as an exogenous substrate as described previously (17). After
20 min at room temperature, kinase reactions were terminated by boiling
in SDS sample buffer before SDS-polyacrylamide gel electrophoresis.
Gels fixed in 50% methanol, 10% acetic acid were subjected to
autoradiography. Quantification of kinase activity was performed using
a Molecular Dynamics Phospho-Imager.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (39K):
[in a new window]
Fig. 1.
Mapping of the NGF-inducible tyrosine
phosphorylation sites on paxillin and c-Crk II. A, each
of the three putative Crk SH2 binding tyrosines in paxillin,
Tyr31, Tyr118, and Tyr182, was
mutated to phenylalanine (paxillin 3Y
3F). 293T cells
were cotransfected with 1.0 µg of cDNA encoding TrkA and 0.2 µg
of either wild-type FLAG-tagged paxillin or mutant as indicated. After
48 h, cells were stimulated with 100 ng/ml NGF, and cellular
lysate (500 µg) was immunoprecipitated with 1.0 µg of anti-FLAG
antibody (M2). Complexes were resolved by SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes,
and blots were probed with either anti-FLAG, anti-paxillin, or
anti-Tyr(P) (anti-pTyr) as indicated. B, 293T
cells were co-transfected as in panel A with TrkA and either
wild-type paxillin or one of the paxillin mutants indicated.
Subsequently, cells were stimulated with NGF, and total cellular lysate
was immunoblotted (20 µg protein) with anti-Tyr(P) antibody to
compare tyrosine phosphorylation of individual paxillin mutants. The
blot was then reprobed with anti-FLAG antibody (M2) or
anti-phospho-TrkA (pTrkA) to verify expression.
C, NGF-inducible Tyr31 phosphorylation on
paxillin is the principal site for c-Crk II binding. 293T cells
expressing TrkA and c-Crk II with either FLAG-tagged wild-type
paxillin or the paxillin triple mutant (paxillin Y
F) were
immunoprecipitated with an anti-Crk antibody and immunoblotted with
either anti-Tyr(P) or anti-FLAG antibodies. Loading controls for the
amount of paxillin, Crk, and phospho-TrkA are shown in the
lower three panels. In the inset, the
relative binding of c-Crk II to wild-type paxillin, Y31F paxillin, or
Y31F,Y118F,Y182F paxillin is compared. Immunoblots were quantified by
laser densitometric scanning of the films. D, 293T cells
were co-transferred with 1.0 µg of cDNA encoding TrkA and 0.2 µg of either c-Crk II or c-Crk Y222F constructs as indicated. After
48 h, cells were treated with 100 ng/ml NGF for 5 min, and the
lysates were immunoblotted with either anti-phospho-Crk
(anti-pCrk) or anti-Tyr(P) antibodies. The blot was then
reprobed with anti-Crk and anti-TrkA antibodies to verify expression
(bottom panels). WB, Western blotting;
IP, immunoprecipitation.
/
) mice. Whereas c-Crk Tyr222 was readily
phosphorylated in NGF-stimulated PC12 cells (39) or in 293T cells
co-expressing c-Crk and TrkA (Fig. 1D), NGF treatment of Abl
(
/
) fibroblasts expressing TrkA and c-Crk II did not lead to
detectable c-Crk II phosphorylation (Fig.
2A, lane 3). However, when wild-type c-Abl expression was reconstituted in Abl
(
/
) fibroblasts by stable gene transfer (Fig. 2A,
Abl kinase panel), NGF-induced c-Crk II phosphorylation was
also restored (Fig. 2A, lane 4). c-Crk II
Tyr222 was not readily detectable in Abl-reconstituted Abl
(
/
) fibroblasts in the absence of TrkA expression and NGF
stimulation (Fig. 2A, inset). These results
suggest that c-Abl is likely an intermediary kinase responsible for
c-Crk II tyrosine phosphorylation following NGF stimulation.

View larger version (34K):
[in a new window]
Fig. 2.
c-Abl is required for NGF-inducible c-Crk II
and paxillin tyrosine phosphorylation. A, c-Abl null
(
/
) fibroblasts were transfected with TrkA and c-Crk II constructs
as indicated. Abl kinase assay was performed as described (top
panel; Ref. 17). In lane 4, c-Abl-deficient cells were
stably transfected with pBabe-c-Abl to obtain c-Abl-reconstituted (Abl
+/+) cells. In the lower two panels, lysates were
immunoblotted with anti-Crk or anti-Tyr(P) (anti-pTyr)
antibodies as indicated to verify c-Crk expression and tyrosine
phosphorylation. In the inset, the extent of c-Crk
Tyr222 phosphorylation (*) in Abl (
/
) cells in the
presence or absence of TrkA is indicated. B, stable
association of paxillin and c-Abl. 293T cells were cotransfected with
cDNAs encoding FLAG-tagged paxillin and one of the plasmids
indicated. Cell lysates were either immunoblotted with anti-Tyr(P) to
compare paxillin tyrosine phosphorylation or reprobed with anti-FLAG
antibody to verify paxillin expression. In the lower two
panels, extracts were immunoprecipitated with anti-FLAG antibody,
divided into equal aliquots, and analyzed for Abl kinase activity (Abl
kinase assay) or immunoblotted with anti-c-Abl antibody 8E9 to verify
expression (anti-Abl WB). C, control mouse embryo
fibroblasts (MEF) (lanes 1 and 2) or
FAK (
/
) fibroblasts (lanes 3 and 4) were
transfected with FLAG-tagged paxillin in the presence or absence of
TrkA construct as indicated. After NGF stimulation, protein extracts
were immunoblotted with anti-Tyr(P) to compare paxillin tyrosine
phosphorylation (top panel). The blot was then reprobed with
anti-FAK and anti-FLAG antibodies to verify appropriate protein
expression (lower two panels). D, c-Abl, but not
FAK or Src, mediates Trk A-dependent paxillin
phosphorylation. 293T cells were contransfected with vectors encoding
paxillin and TrkA and one of the kinase-deficient constructs encoding
c-Abl (K290M), FAK (K454M), or c-Src (K416M) as indicated. Cell lysates
were immunoblotted with anti-Tyr(P) to compare paxillin tyrosine
phosphorylation. The blot was sequentially reprobed with the indicated
antibodies to verify appropriate kinase expression. WB,
Western blotting; IP, immunoprecipitation.
/
) embryos (49) were cotransfected with TrkA and wild-type paxillin (Fig.
2C). Trk A-dependent tyrosine phosphorylation of
paxillin was evident in FAK (
/
) cells, and the extent of
phosphorylation was similar in cells expressing or lacking FAK (Fig.
2C, lanes 2 and 4). Moreover, when
paxillin was co-transfected with TrkA in 293T cells in the presence of
either kinase-deficient c-Abl (K290M c-Abl), kinase-deficient FAK
(K454M FAK), or kinase-deficient-Src (K295M c-Src), K290M c-Abl
exhibited the most significant inhibition in Trk A-induced paxillin
phosphorylation (Fig. 2D). These results suggest that
different activating stimuli may utilize distinct intermediate
non-receptor tyrosine kinases for the tyrosine phosphorylation of
paxillin; Src and FAK for integrin and c-Abl for NGF.

View larger version (25K):
[in a new window]
Fig. 3.
Expression of c-Crk Y222F leads to increased
paxillin tyrosine phosphorylation and results in enhanced Crk/paxillin
association. A, 293T cells were cotransfected with
plasmid vectors encoding FLAG-tagged paxillin and TrkA together with
wild-type c-Crk II or c-Crk Y222F as indicated. After NGF stimulation,
protein extracts (20 µg) were immunoblotted with anti-Tyr(P)
(anti-pTyr) to compare paxillin tyrosine phosphorylation
(top panel). The numbers in
parentheses indicate the relative intensity of the
immunopositive signal as determined by densitometry. The membrane was
also reprobed with antibodies to FLAG, Crk, or pTrk to verify
appropriate expression. B, c-Crk Y222F increases complex
formation between Crk and paxillin. Lysates from 293T cell
cotransfectants (Fig. 3A, lanes 2 and
3) were immunoprecipitated with anti-FLAG antibody, divided
into equal aliquots, and immunoblotted with either anti-pCrk or
anti-Crk antibodies. The top panel (anti-pCrk
spnt) represents the supernatant fraction recovered from the
anti-FLAG immunoprecipitation. WB, Western blotting;
IP, immunoprecipitation.

View larger version (21K):
[in a new window]
Fig. 4.
Expression of c-Crk Y222F enhances the
association of Crk with Abl and with paxillin. A, 293T
cells were cotransfected with wild-type c-Abl and one of the c-Crk
expression plasmids as indicated. Cellular lysates (1.0 mg of protein)
were immunoprecipitated with anti-Crk antibody, divided into equal
aliquots, and analyzed for for c-Abl/c-Crk co-immunoprecipitation and
c-Abl kinase activity (top two panels). The blot was
reprobed with anti-Crk antibodies to verify appropriate Crk protein
expression in the immunoprecipitates. Total cellular lysates were
Western-blotted with an anti-Abl antibody to verify c-Abl protein
expression. In the inset, the gels were quantified with a
Molecular Dynamics PhosphorImagerTM, and the data are expressed as
average ± S.E. of three experiments. B, 293T cells
were cotransfected with plasmid vectors encoding FLAG-tagged paxillin
and the indicated plasmids. Cell lysates (1.0 mg of protein) were
immunoprecipitated with an anti-FLAG antibody, and immune complexes
were Western-blotted with the anti-cAbl antibody 8E9 or reprobed with
anti-FLAG antibody to verify paxillin expression. The lower two
panels showed the appropriate expression of c-Abl and wild-type
c-Crk II or c-Crk Y222F in the total lysate. WB, Western
blotting; IP, immunoprecipitation.

View larger version (38K):
[in a new window]
Fig. 5.
Effects of NGF on the kinetics of tyrosine
phosphorylation of c-Crk II and paxillin in PC12 cells.
A, serum-starved TrkA-expressing PC12-615 cells were
stimulated with 100 ng/ml NGF for up to 60 min. Cells were then lysed
and immunoblotted with anti-Tyr(P) (anti-pTyr) antibody.
Tyrosine-phosphorylated TrkA, paxillin and the mitogen-activated
protein kinases (ERK) are indicated on the right.
B and C, the same lysates as shown in Fig.
6A were immunoprecipitated with either anti-Crk
(B) or anti-paxillin (C) antibodies. The immune
complexes were Western-blotted with anti-Tyr(P) antibodies to show
NGF-inducible tyrosine phosphorylation and endogenous c-Crk II and
paxillin to show expression. D, PC12-615 cells were infected
with recombinant retroviral vectors for GFP (lane 1),
wild-type c-Crk II (lanes 2 and 3), or c-Crk
Y222F (lanes 4 and 5). After 48 h, cells
were treated with or without 100 ng/ml NGF for 2 min and rapidly lysed
in ice-cold HNTG buffer. The lysates were immunoprecipitated with
anti-Crk antibody, and immunoblotted with an anti-paxillin antibody to
compare paxillin-Crk interaction (upper panel) or with an
anti-Crk antibody to verify Crk expression (lower panel).
The arrow indicates the coprecipitating pool of paxillin.
WB, Western blotting; IP,
immunoprecipitation.

View larger version (96K):
[in a new window]
Fig. 6.
c-Crk Y222F inhibits
NGF-dependent neuritogenesis and causes paxillin
mislocalization. A, Wild-type and c-Crk
Y222F-expressing PC12 cells were treated for 5 min in the
presence or absence of 100 ng/ml NGF as indicated. The lysates were
immunoblotted with anti-Crk to verify Crk overexpression or
immunoprecipitated with anti-Crk antibodies to detect phosphorylated
c-Crk II (anti-Tyr(P) (anti-pTyr) panel).
B, PC12 cells (panels i-iii), c-Crk II-expressing
PC12 cells (panels iv-vi), or c-Crk Y222F-expressing PC12
cells (panels vii-ix) were treated with 50 ng/ml NGF for
72 h (top 3 panels) or 36 h (bottom 6 panels). For immunofluorescence, cells were fixed,
permeabilized, and stained with either rhodamine-conjugated phalloidin
(panels ii, v, and viii) or
anti-paxillin monoclonal antibody (panels iii,
vi, ix). WB, Western blotting;
IP, immunoprecipitation.

View larger version (18K):
[in a new window]
Fig. 7.
c-Crk Y222F impairs integrin-mediated cell
attachment and causes detachment of PC12 cells. A,
control PC12 cells, c-Crk II, or c-Crk Y222F-expressing PC12 cells were
plated for 6 h on either 1.0 mg/ml BSA or 2 mg/ml collagen
IV-coated surfaces as indicated and assayed for attachment by a
quantitative cell attachment assay. Each value represents the mean of
determinations made in triplicate wells performed in parallel and
expressed as the percentage of attachment to the positive control
(i.e. poly-D-lysine). Vertical error
bars indicate S.D. B, serial x-y confocal
sections obtained from parental PC12 cells, c-Crk II expressing PC12
cells, or c-Crk Y222F-expressing PC12 cells (from left to right). The
smaller panels are cross-section representatives, and the
area to height ratios are indicated by the numbers below
each panel. C, PC12 cells were infected with
recombinant retroviral vectors expressing GFP alone or coexpressing GFP
with either wild-type c-Crk II or c-Crk Y222F as in Fig. 6. The
percentage of GFP-positive cells that remained adherent
versus the percentage removed in the wash were quantified by
fluorescence-activated cell sorter analysis gated with a fluorescein
isothiocyanate filter. Data are plotted as the average ratio of
detached/attached cells plated in triplicate and are the average of two
independent experiments. In the inset, GFP-positive cells
were FACSorted and collected. Detergent lysates were prepared, and 20 µg of protein was immunoblotted with either anti-GFP or anti-Crk
antibodies to demonstrate coexpression. WB, Western
blotting.

View larger version (25K):
[in a new window]
Fig. 8.
A model for the c-Crk II phosphorylation
switch. The cycle represents a combination of features that may be
attributable to dynamic cytoskeletal changes following NGF stimulation.
c-Abl, which is shown in a complex with TrkA (47), transduces an
intracellular signal that results in the sequential phosphorylation of
c-Crk Tyr222 and paxillin Tyr31 (panel
A). In this model, c-Crk Tyr222 is rate-limiting for
the dissociation of cellular complexes of c-Crk and paxillin as well as
c-Crk and Abl (panel B). Subsequently, a dephosphorylated
Crk molecular may associate again with Abl to establish another cycle
of Crk/paxillin turnover (panel C).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, LAR, and PTEN, have been
implicated in the regulation of cell adhesion and migration by
dephosphorylating focal adhesions proteins such as FAK,
p130cas, and paxillin (67-71). For example, fibroblasts
derived from PTP-PEST (
/
) mice display hyperphosphorylated
paxillin and a concomitant decrease in cell adhesion and motility,
suggesting that PTP-PEST plays a role in the breakdown of focal
adhesions (68). In the c-Crk Y222F-expressing PC12 cells,
hyperphosphorylated paxillin is unable to interact with focal contacts
and actin microfilaments in the lamellipodia of advancing growth cones.
Therefore, like c-Crk II, the phosphorylation status of paxillin is
tightly coupled to cytoskeletal dynamics, since both hypo- and
hyperphosphorylated paxillin might be disruptive for focal adhesion
complex formation. In view of the phosphotyrosine-dependent
on/off interaction between paxillin and c-Crk II, it will be
interesting to determine whether the putative PTPases specific for
c-Crk II may also play a direct role in reversing paxillin phosphorylation.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Christopher Turner, Steven Hanks, David Baltimore, David Kaplan, Hisataka Sabe, Tohru Ouchi, and Tadashi Yamamoto for generous gifts of reagents and Kathrin Kirsch and Hidesaburo Hanafusa for critical comments on the manuscript.
| |
FOOTNOTES |
|---|
* This research was supported in part by National Institutes of Health Grant GM55760 and a Muscular Dystrophy Association grant (to R. B. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally.
Supported by Public Health Service Grant NS30687 and a fund
from the March of Dimes.

To whom correspondence should be addressed: The New
Jersey Medical School, 185 S. Orange Ave., MSB, E-647, University
Heights, Newark, NJ 07103-2714. Tel.: 973-972-4497; E-mail:
birgera@umdnj.edu.
Published, JBC Papers in Press, May 23, 2000, DOI 10.1074/jbc.M000711200
2 M. Escalante and R. B. Birge, unpublished result.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: SH2, Src homology 2; FAK, focal adhesion kinase; NGF, nerve growth factor; DMEM, Dulbecco's modified Eagle's medium; GFP, green fluorescent protein; PBS, phosphate-buffered saline; BSA, bovine serum albumin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Birge, R. B., Knudsen, B., Besser, D., and Hanafusa, H. (1996) Genes Cells 1, 595-613 |
| 2. | Buday, L. (1999) Biochim. Biophys. Acta 1422, 187-204 |
| 3. | Feller, S. M., Posern, G., Voss, J., Kardinal, C., Sakkab, D., Zheng, J., and Knudsen, B. (1998) J. Cell. Physiol. 177, 535-552 |
| 4. | Hempstead, B. L., Birge, R. B., Fajardo, J. E., Glassman, R., Mahadeo, D., Kraemer, R., and Hanafusa, H. (1994) Mol. Cell. Biol. 14, 1964-1971 |
| 5. | Teng, K. K., Courtney, J. C., van Bergen Henegouwen, P., Birge, R. B., and Hempstead, B. L. (1996) Mol. Cell. Neurosci. 8, 157-170 |
| 6. | Weinstein, D. E., Dobrenis, K., and Birge, R. B. (1999) Dev. Brain Res. 116, 29-39 |
| 7. | Nievers, M. G., Birge, R. B., Greulich, H., Verkleij, A. J., Hanafusa, H., and van Bergen Henegouwen, P. (1997) J. Cell Sci. 110, 389-399 |
| 8. | Altun-Gultekin, Z. F., Chandriani, S., Bougeret, C., Ischizaki, T., de Graaf, P., van Bergen Henegouwen, P., Hanafusa, J. A., Wagner, J. A., and Birge, R. B. (1998) Mol. Cell. Biol. 18, 3044-3058 |
| 9. | Reichman, C., Mayer, B., Keshav, S., and Hanafusa, H. (1992) Cell Growth Differ. 3, 451-460 |
| 10. | Hoeve, J. T., Morris, C., Heisterkamp, M., and Groffen, J. (1993) Oncogene 8, 2469-2474 |
| 11. | Kiyokawa, E., Hashimoto, Y., Kobayashi, S., Sugimura, H., Kurata, T., and Matsuda, M. (1998) Genes Dev. 12, 3331-3336 |
| 12. | Cherish, D. A., Leng, J., and Klemke, R. L. (1999) J. Cell Biol. 146, 1107-1116 |
| 13. | Nakashima, N., Rose, D. W., Xiao, S., Egawa, K., Martin, S. S., Haruta, T., Saltiel, A. R., and Olefsky, J. M. (1999) J. Biol. Chem. 274, 3001-3008 |
| 14. | Klemke, R. L., Leng, J., Molander, R., Brooks, P. C., Vuori, K., and Cheresh, D. A. (1998) J. Cell Biol. 140, 961-972 |
| 15. | Oktay, M., Wary, K. K., Dans, M., Birge, R. B., and Giancotti, F. G. (1999) J. Cell Biol. 145, 1461-1469 |
| 16. | Matsuda, M., Tanaka, S., Nagata, S., Kojima, A., Kurata, T., and Shibuya, M. (1992) Mol. Cell. Biol. 12, 3482-3489 |
| 17. | Feller, S. M., Knudsen, B., and Hanafusa, H. (1994) EMBO J. 13, 2341-2351 |
| 18. | Senechal, K., Heaney, C., Druker, B., and Sawyers, C. L. (1998) Mol. Cell. Biol. 18, 5082-5090 |
| 19. | Rosen, M. K., Yamazaki, T., Gish, G. D., Kay, C. M., Pawson, T., and Kay, L. E. (1995) Nature 374, 477-479 |
| 20. | Thomas, J. E., Soriano, P., and Brugge, J. S. (1991) Science 254, 568-571 |
| 21. | Guan, J. L., and Shalloway, D. (1992) Nature 358, 690-692 |
| 22. | Lev, S., Moreno, H., Martinez, R., Canoll, P., Peles, E., Musaacchio, J. M., Plowman, G. D., Rudy, B., and Schlessinger, J. (1995) Nature 376, 737-744 |
| 23. | Lewis, J. M., and Schwartz, M. A. (1998) J. Biol. Chem. 273, 14225-14230 |
| 24. | Schaller, M. D., Hildebrand, J. D., Shannon, J. D., Fox, J. W., Vines, R. R., and Parsons, J. T. (1994) Mol. Cell. Biol. 14, 1680-1688 |
| 25. | Giancotti, F. G., and Rouslahti, E. (1999) Science 285, 1028-1032 |
| 26. | Turner, C. E., and Miller, J. T. (1994) J. Cell Sci. 107, 1583-1591 |
| 27. | Nojima, Y., Morino, N., Mimura, T., Hamasaki, K., Furuya, H., Sakai, R., Sato, T., Tachibana, K., Morimoto, C., Yazaki, Y., and Hirai, H. (1995) J. Biol. Chem. 270, 15398-15402 |
| 28. | Schlaepfer, D. D., Hauck, C. R., and Sieg, D. J. (1999) Prog. Biophys. Mol. Biol. 71, 435-478 |
| 29. | Birge, R., Fajardo, J., Reichman, C., Shoelson, S., Songyang, Z., Cantley, L., and Hanafusa, H. (1993) Mol. Cell. Biol. 13, 4648-4656 |
| 30. | Schaller, M. D., and Parsons, J. T. (1995) Mol. Cell. Biol. 15, 2635-2645 |
| 31. | Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756 |
| 32. | Kiyokawa, E., Hashimoto, Y., Kurata, T., Sugimura, H., and Matsuda, M. (1998) J. Biol. Chem. 273, 24479-24484 |
| 33. | Petit, V., Boyer, B., Lentz, D., Turner, C. E., Thiery, J. P., and Valles, V. M. (2000) J. Cell Biol. 148, 957-970 |
| 34. | Abedi, H., Dawes, K. E., and Zachary, I. (1995) J. Biol. Chem. 270, 11367-11376 |
| 35. | Casamassima, A., and Rozengurt, E. (1998) J. Biol. Chem. 273, 26149-26156 |
| 36. | Ojaniemi, M., and Vuori, K. (1997) J. Biol. Chem. 272, 25993-25998 |
| 37. | Greene, L., and Tischler, A. (1982) Adv. Cell. Neurobiol. 3, 373-414 |
| 38. | Altun-Gultekin, Z. F., and Wagner, J. A. (1996) J. Neurosci. Res. 44, 308-327 |
| 39. | Ribon, V., and Saltiel, A. R. (1996) J. Biol. Chem. 271, 7375-7380 |
| 40. | Hashimoto, Y., Katayama, H., Kiyokawa, E., Ota, S., Kurata, T., Gotoh, N., Otsuka, N., Shibata, M., and Matsuda, M. (1998) J. Biol. Chem. 273, 17186-17191 |
| 41. | Hempstead, B. L., Rabin, S. J., Kaplan, L., Reid, S., Parada, L. F., and Kaplan, D. R. (1992) Neuron 9, 883-896 |
| 42. | Mayer, B. J., Hirai, H., and Sakai, R. (1995) Curr. Biol. 5, 296-305 |
| 43. | Ben-Neriah, Y., Bernards, A., Paskind, M., Daley, G. Q., and Baltimore, D. (1986) Cell 44, 577-586 |
| 44. | Mayer, B. J., and Baltimore, D. (1994) Mol. Cell. Biol. 14, 2883-2894 |
| 45. | Tomaselli, K. J., Damsky, C. H., and Reichardt, L. F. (1987) J. Cell Biol. 105, 2347-2358 |
| 46. | Melamed, I., Turne, C. E., Aktories, K., Kaplan, D. R., and Gelfand, E. W. (1995) J. Exp. Med. 181, 1071-1079 |
| 47. | Yano, H., Cong, F.., Birge, R. B., Goff, S. G., and Chao, M. V. (2000) J. Neurosci. Res. 59, 356-364 |
| 48. | Hildebrand, J. D., Schaller, M. D., and Parsons, J. T. (1995) Mol. Biol. Cell. 6, 637-647 |
| 49. | Ilac, D., Furuta, S., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., and Alzawa, S. (1995) Nature 377, 539-544 |
| 50. | Hynes, R. O. (1992) Cell 69, 11-25 |
| 51. | Richardson, A., Malik, R. K., Hildebrand, J. D., and Parsons, J. T. (1997) Mol. Cell. Biol. 17, 6906-6914 |
| 52. | Tanaka, S., Ouchi, T., and Hanafusa, H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2356-2361 |
| 53. | Dolfi, F., Garcia-Guzman, M., Ojaniemi, M., Nakamura, H., Matsuda, M., and Vuori, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15394-15399 |
| 54. | Ling, P., Yao, Z., Meyer, C. F., Wang, X. S., Oehrl, W., Feller, S. M., and Tan, T. H. (1999) Mol. Cell. Biol. 19, 1359-1368 |
| 55. | Sakai, R., Nakamoto, T., Ozawa, K., Aizawa, S., and Hirai, H. (1997) Oncogene 14, 1419-1426 |
| 56. | Salgia, R., Uemura, N., Okuda, K., Li, J.-L., Pisick, E., Sattler, M., de Jong, R., Druker, B., Heisterkamp, N., Chen, J., Groffen, L. B., and Griffin, J. D. (1995) J. Biol. Chem. 270, 29145-29150 |
| 57. | Torres, M., and Bogenmann, E. (1996) Oncogene 11, 77-86 |
| 58. | Meakin, S. O., MacDonald, J. I. S., Gryz, E. A., Kubu, C. J., |